

**THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION.** If you are in any doubt as to the action you should take, you are recommended immediately to seek your own financial advice from your stockbroker, solicitor, accountant or other independent professional adviser duly authorised under the Financial Services and Markets Act 2000 if you are resident in the United Kingdom or, if not, from another appropriately authorised independent financial adviser.

If you have sold or transferred all of your shares in Clinigen Group plc, please send this document and any accompanying documents as soon as possible to the purchaser or transferee of those shares or to the stockbroker, bank or other agent through whom the sale or transfer was effected for onward transmission to the purchaser or transferee.

**CLINIGEN**  
**GROUP PLC**

*(incorporated and registered in  
England and Wales under  
company number 06771928)*

# NOTICE OF THE 2021 ANNUAL GENERAL MEETING

Notice of the Annual General Meeting ('AGM') of Clinigen Group plc (the 'Company'), to be held at The Argyll Club, 85 Gresham Street, London EC2V 7NQ at 10:00am on 24 November 2021, is set out on pages 6 to 8 of this document. Your attention is drawn to the letter from the Company's Chairman on page 2 of this document.

Whether or not you propose to attend the AGM, please complete and submit a proxy appointment form or electronic proxy appointment instruction in accordance with the notes to the Notice of AGM set out on page 8. To be valid, the proxy appointment form or electronic proxy appointment instruction must be received at the address for delivery specified in the notes by 10:00am on 22 November 2021.

We are closely monitoring the ongoing impact of the COVID-19 pandemic and we are conscious of the potential for travel or other restrictions to be introduced which may impact the AGM. If any changes are required to the format and/or the arrangements for the 2021 AGM after the date of this notice, we will notify shareholders as soon as practicable. We encourage shareholders to monitor the Company's website (<https://www.clinigengroup.com/investors/shareholder-services/agm>) for any future updates.

# LETTER FROM THE CHAIRMAN

Clinigen Group plc  
Pitcairn House  
Crown Square, Centrum 100  
Burton-on-Trent  
Staffordshire DE14 2WW

30 September 2021

Dear shareholder

## 2021 Annual Report and Accounts, and AGM

In my first letter to shareholders as Chairman of Clinigen Group plc, I am pleased to report that our Annual Report and Accounts for the year ended 30 June 2021 ('2021 Annual Report and Accounts') and Notice of AGM have now been published.

A copy of the 2021 Annual Report and Accounts is enclosed. The document can also be accessed via the investors' section of our website ([www.clinigengroup.com](http://www.clinigengroup.com)).

This year, we are planning to hold our AGM at The Argyll Club, 85 Gresham Street, London EC2V 7NQ at 10:00am on 24 November 2021. At the time of writing it is uncertain what regulations or public health guidance may be in place at the time of the AGM which may restrict the number of people who can gather in public. Any changes to the arrangements for the AGM will be communicated to shareholders before the AGM through our website (<https://www.clinigengroup.com/investors/shareholder-services/aggm>) and, where appropriate, by a regulatory information service announcement. In light of this uncertainty, we do strongly encourage shareholders to submit a proxy vote in advance of the AGM and to appoint the Chairman of the meeting as their proxy, rather than a named person who, if circumstances change, may not be able to attend the meeting. Further details on how to do this are set out on page 8. Your Board understands that many of the attendees of our AGMs in past years, even if their health and the then current regulations permit, would not want to travel into central London to attend the AGM this year. In view of this, this year the Company will upload to our website (<https://www.clinigengroup.com/investors/shareholder-services/aggm>) a presentation to shareholders by our Chief Executive Officer, Shaun Chilton, on the business of the Clinigen Group and its performance over the last 12 months. We also know that some attendees appreciate the opportunity to ask Board members questions. If you have any questions that you would like to ask, we would encourage you to email them to [aggm@clinigengroup.com](mailto:aggm@clinigengroup.com) with 'AGM 2021' in the heading. We will then collate the answers to the questions received and upload them to our website (<https://www.clinigengroup.com/investors/shareholder-services/aggm>) following the AGM or, if more appropriate, reply to the questioner directly.

If you do plan to attend the AGM in person this year, please notify us in advance of your intention to attend by sending an email with your name, address and confirmation that you wish to attend the AGM to [aggm@clinigengroup.com](mailto:aggm@clinigengroup.com) with 'AGM 2021 - attendance' in the heading.

The formal Notice of AGM is set out on pages 6 to 8 of this document and contains the proposed resolutions.

## Action to be taken

If you are unable to attend the AGM, you can still vote on the proposed resolutions by appointing a proxy. To appoint a proxy:

- (a) you can complete the enclosed proxy appointment form, in accordance with the instructions printed on it, and return it (together with any power of attorney or other authority under which it is signed, or a certified copy of such item) to our Registrar, Equiniti, at Aspect House, Spencer Road, Lancing BN99 6DA; or
- (b) if you hold your shares in CREST, you can alternatively submit an electronic proxy appointment instruction to our Registrar (ID RA19) through the CREST system in accordance with the CREST Manual.

In either case, the proxy appointment form should be returned, or the electronic proxy appointment instruction transmitted, as soon as possible and in any event so as to be received by our Registrar by 10:00am on 22 November 2021.

You are requested (whether or not you intend to be present at the AGM) to appoint a proxy. Appointment of a proxy will not prevent you from attending, speaking and voting in person at the AGM, should you wish to do so.

## Recommendation

You will find on pages 3 to 5 of this document explanatory notes in relation to the various resolutions which are set out in the Notice of AGM. The Board considers that each of these resolutions is in the best interests of the Company and its shareholders as a whole. Accordingly, all Directors intend to vote in favour of each resolution in respect of their own beneficial holdings (with the exception of resolutions 4 to 9, in respect of which each Director will not vote on the relevant resolution relating to their own reappointment). The Directors unanimously recommend that shareholders vote in favour of all the proposed resolutions.

Yours faithfully



**Elmar Schnee**  
Chairman

# EXPLANATORY NOTES TO THE BUSINESS OF THE AGM

## Resolution 1 – Receipt of the 2021 Annual Report and Accounts

The Companies Act 2006 requires the Directors of the Company to lay before the shareholders in general meeting copies of its annual accounts, the strategic report (if any), the Directors' report and the independent auditors' report on those accounts in respect of each financial year. In accordance with best practice, the Company proposes, as an ordinary resolution, a resolution to receive its 2021 Annual Report and Accounts.

## Resolution 2 – Approval of Remuneration Report

As a matter of good corporate governance, the Company has elected to seek shareholder approval at this AGM (and at each subsequent AGM), by way of ordinary resolution, for the part of its Directors' Remuneration Report which describes how the Company's Directors' remuneration policy has been implemented during the previous financial year.

The relevant part of the Directors' Remuneration Report is set out on pages 76 to 85 of the 2021 Annual Report and Accounts.

Please note that this vote is advisory only, therefore it does not affect the historical remuneration paid to any individual Director.

## Resolution 3 – Declaration of a final dividend

The Directors recommend a final dividend of 5.46p per ordinary share. If approved by ordinary resolution of the shareholders, the dividend will be paid on 4 January 2022 to shareholders on the register at close of business on 3 December 2021.

## Resolutions 4 to 9 – Election and re-election of Directors

Peter Allen stood down as independent Non-Executive Chairman of the Company on 1 September 2021. Peter had served as Chairman since the Company's IPO in September 2012. Ian Nicholson will step down at the AGM. Ian joined the Board in September 2012 and has served as a member of the Nomination and Audit and Risk Committees and chaired the Remuneration Committee. Anne Hyland stepped down from her position as Senior Independent Director on 3 August 2021, but remains Chair of the Audit and Risk Committee and an independent Non-Executive Director. Nick Keher stood down from his position as Chief Financial Officer of the Company on 25 August 2021.

In accordance with the Company's Articles of Association, any Director appointed by the Board during the year is required to retire at the next Annual General Meeting following his or her appointment. Such Director is eligible to stand for election at that Annual General Meeting. Elmar Schnee was appointed as an independent Non-Executive Director of the Company on 3 August 2021 and assumed the role of Chairman with effect from 1 September 2021. On 3 August 2021, Ian Johnson was appointed as an independent Non-Executive Director and Senior Independent Director of the Company. Sharon Curran was appointed as a new independent Non-Executive Director with effect from 27 April 2021. Elmar Schnee, Ian Johnson and Sharon Curran were therefore appointed as Directors prior to the AGM and, as such, are obliged, under the aforementioned requirement of the Company's Articles of Association, to retire at the AGM and seek election by shareholders. Resolutions 4, 5 and 6 deal with the election of the three new Directors. Brief biographical details of Elmar Schnee, Ian Johnson and Sharon Curran are set out below.

Elmar Schnee most recently served on the Board of Jazz Pharmaceuticals from August 2014 until July 2021. He serves as a Non-Executive Director on a number of other pharmaceutical company Boards, including Santhera AG and Calliditas AB, alongside several other private biopharma companies. Prior to this, his career spanned a range of senior roles at companies including Merck KGaA, including as General Partner and a member of the executive Board, and at Merck Serono as CEO. He has also held senior management positions at UCB and Sanofi. He holds both a bachelor's degree in marketing and a master's degree in marketing and general management from the Swiss Institute of Business Administration in Zurich.

Ian Johnson currently serves as Executive Chairman of Circassia Group and Non-Executive Chairman of Redcentric plc. He has recently announced his intention to step down from Redcentric. Mr Johnson also served as Executive Chairman of Bioquell PLC and Non-Executive Chairman of Quantum Pharma PLC, Cyprotex PLC and Celsis Group Ltd. He also served as Non-Executive Director of Ergomed PLC and on the Boards of AIM-listed companies Evans Analytical Group and AOI Medical Inc, amongst other listed companies. Mr Johnson was a founder and Chief Executive Officer of Biotrace International plc, which was an AIM-listed company prior to its sale to 3M in 2006.

Sharon Curran is currently a Non-Executive Director for Circassia Group plc, where she is Chair of the Remuneration Committee. She is also on the Board of Morphosys AG (Audit & Risk Committee). Before taking these roles, Ms Curran was VP, Global Marketing and Commercial Operations at AbbVie where she worked from 2012 to 2017. Whilst there, she

# EXPLANATORY NOTES TO THE BUSINESS OF THE AGM

was on the ethics & compliance committee, involved in portfolio strategy and was part of the global crisis management team. Previously, Ms Curran was Global Brand and Regional Commercial Director at Abbott Pharmaceuticals (2009-2012) and before then, she was Divisional Head, Strategy & Operations (Ireland & UK Affiliate) for Eli Lilly (1999-2008). Ms Curran has an M.Sc in Business Administration from Trinity College, Dublin and a B.Sc in Biotechnology from Dublin City University. She is a Chartered Director, accredited by the Institute of Directors, London.

In relation to resolutions 7 to 9, the Company's Articles of Association state that one-third of the Directors must stand for re-election by shareholders annually in rotation. However, to underline their accountability to shareholders and the Board's commitment to appropriate corporate governance, all Directors will stand for re-election at every AGM. Resolutions 7 to 9 therefore deal with the re-election of the remaining Directors, namely Anne Hyland (resolution 7), Alan Boyd (resolution 8) and Shaun Chilton (resolution 9).

Biographical details of all the Company's Directors as at the date of this document can be found on pages 62 to 63 of the 2021 Annual Report and Accounts. In the Board's view, these illustrate why each Director's contribution is, and continues to be, important to the Company's long-term sustainable success.

Resolutions 4, 5, 6, 7, 8 and 9 will be proposed as ordinary resolutions.

The Board believes that those Directors who are currently serving on the Board and who are seeking re-election this year continue to be effective, make a positive contribution to the Board and demonstrate commitment to their roles.

## **Resolutions 10 and 11 – Auditors' reappointment and remuneration**

At or before each general meeting at which the Annual Report and Accounts for a financial year are laid, the Company is required to appoint auditors to serve for the following financial year. PricewaterhouseCoopers LLP have indicated their willingness to continue as the Company's auditors. Resolution 10 is an ordinary resolution to reappoint them. Resolution 11 is an ordinary resolution giving the Directors the discretion to determine the auditors' remuneration.

## **Resolution 12 – Political donation**

Part 14 of the Companies Act 2006 imposes restrictions on a company making political donations to any political party, other political organisation or independent election candidate, or incurring political expenditure, unless authorised to do so at a general meeting. It has always been the Company's policy that it does not make political donations or incur political expenditure, in each case within the commonly understood meaning of such expressions. This remains the case and the Directors have no intention of changing that policy. However, the Companies Act 2006 includes broad and potentially ambiguous definitions of the terms 'political donation' and 'political expenditure', which may apply to some normal business activities which would not generally be considered to be political in nature.

As previously, the Board considers that, as a precautionary measure, it is therefore prudent to obtain shareholder approval, by way of ordinary resolution, to make political donations and/or to incur political expenditure, in each case within the meaning of the Companies Act 2006, up to the limit specified in the resolution. The Directors intend to seek renewal of this approval at future AGMs, but wish to emphasise that the proposed resolution is sought on a purely precautionary basis in order to avoid inadvertent contravention of the Companies Act 2006. The Board has no intention of entering into any party political activities.

## **Resolution 13 – Authority to allot shares**

The Directors currently have an authority to allot shares in the Company and to grant rights to subscribe for or convert any securities into shares in the Company. This authority is due to expire at the AGM. The Board is seeking, by ordinary resolution, to renew that authority over ordinary shares up to a maximum nominal amount of £44,338.45, representing approximately 33.33% of the Company's issued share capital as at 14 September 2021 (being the latest practicable date prior to publication of this document). As at that same date, the Company did not hold any treasury shares. If approved by shareholders, this authority will expire on 24 February 2023 or, if earlier, at the conclusion of the Company's next AGM. The Directors have no present intention of exercising this authority.

## **Resolutions 14 and 15 – Disapplication of statutory pre-emption rights**

Resolutions 14 and 15 are special resolutions which, if passed by the shareholders, will enable the Directors, during the period until 24 February 2023 (or, if earlier, the conclusion of the Company's next AGM), to allot ordinary shares, or to sell any ordinary shares out of treasury, for cash, without first offering those shares to existing shareholders in proportion to their existing holdings.

## EXPLANATORY NOTES TO THE BUSINESS OF THE AGM

These resolutions essentially replicate the authorities which were granted at last year's AGM (and which will expire at the forthcoming AGM). Such authorities reflect the Statement of Principles published by The Pre-Emption Group in March 2015, which provides that a company may seek power to issue on a non-pre-emptive basis for cash in any one year shares representing: (i) no more than 5% of the company's issued ordinary share capital; and (ii) no more than an additional 5% of the company's issued ordinary share capital provided that such additional power is only used in connection with the financing or refinancing of an acquisition or specified capital investment.

The 2015 Statement of Principles defines a 'specified capital investment' as 'one or more specific capital investment related uses for the proceeds of an issuance of equity securities, in respect of which sufficient information regarding the effect of the transaction on the company, the assets the subject of the transaction and (where appropriate) the profits attributable to them is made available to shareholders to enable them to reach an assessment of the potential return'. Items that are regarded as operating expenditure rather than capital expenditure will not typically be regarded as falling within the term 'specified capital investment'.

Resolution 14 is to be proposed as a special resolution. If this resolution is passed by shareholders, it will permit the Board to allot ordinary shares for cash on a non-pre-emptive basis both in connection with a rights issue or similar pre-emptive issue and, otherwise than in connection with any such issue, up to a maximum nominal amount of £6,651.43. This amount represents approximately 5% of the Company's issued ordinary share capital as at 14 September 2021 (being the latest practicable date prior to publication of this document). This customary resolution will permit the Board to allot ordinary shares for cash, up to the specified level, in any circumstances (whether or not in connection with an acquisition or specified capital investment).

Resolution 15 is to be proposed as a separate special resolution. If this resolution is passed by shareholders, it will afford the Board an additional power to allot ordinary shares for cash on a non-pre-emptive basis up to a further maximum nominal amount of £6,651.43. This amount again represents approximately 5% of the Company's issued ordinary share capital as at 14 September 2021. The Board will use the power conferred by resolution 15 only in connection with the financing or refinancing of an acquisition or a specified capital investment which is announced contemporaneously with the issue, or which has taken place in the preceding six-month period and is disclosed in the announcement of the issue.

The Directors confirm their intention to follow the provisions of the 2015 Statement of Principles regarding cumulative usage of authorities within a rolling three-year period. Those provisions state that a company should not issue shares for cash representing more than 7.5% of the company's issued share capital in any rolling three-year period, other than to existing shareholders, without prior consultation with shareholders. This limit excludes any ordinary shares issued pursuant to a general disapplication of pre-emption rights in connection with an acquisition or specified capital investment.

# NOTICE OF 2021 AGM

## CLINIGEN GROUP PLC

Notice is hereby given that the 2021 AGM of the members of Clinigen Group plc will be held at The Argyll Club, 85 Gresham Street, London EC2V 7NQ at 10:00am on 24 November 2021 for the purposes set out below.

Resolutions 1 to 13 will be proposed as ordinary resolutions. Resolutions 14 and 15 will be proposed as special resolutions.

1. To receive the audited financial statements and the Auditors' and Directors' Reports for the year ended 30 June 2021.
2. To approve the Directors' Remuneration Report (other than the part containing the Directors' remuneration policy) for the year ended 30 June 2021.
3. To declare a final dividend of 5.46p per share for the year ended 30 June 2021.
4. To elect Elmar Schnee as a Director.
5. To elect Ian Johnson as a Director.
6. To elect Sharon Curran as a Director.
7. To re-elect Anne Hyland as a Director.
8. To re-elect Alan Boyd as a Director.
9. To re-elect Shaun Chilton as a Director.
10. To reappoint PricewaterhouseCoopers LLP as auditors.
11. To authorise the Directors to determine the auditors' remuneration.
12. That, from the date of this resolution until the earlier of 24 February 2023 and the conclusion of the Company's next AGM, the Company and all companies which are its subsidiaries at any time during such period are authorised:
  - (a) to make donations to political parties and/or independent election candidates;
  - (b) to make donations to political organisations other than political parties; and
  - (c) to incur political expenditure,  
  
up to an aggregate total amount of £50,000, with the amount authorised for each of heads (a) to (c) above being limited to the same total. Any such amounts may comprise sums paid or incurred in one or more currencies. Any sum paid or incurred in a currency other than sterling shall be converted into sterling at such rate as the Board may decide is appropriate. Terms used in this resolution have, where applicable, the meanings that they are given in Part 14 of the Companies Act 2006 on 'Control of political donations and expenditure'.
13. That the Directors are generally and unconditionally authorised pursuant to section 551 of the Companies Act 2006 to exercise all the powers of the Company to allot shares in the Company and to grant rights to subscribe for or to convert any security into such shares ('Allotment Rights'), but so that:
  - (a) the maximum amount of shares that may be allotted or made the subject of Allotment Rights under this authority are shares with an aggregate nominal value of £44,338.45;
  - (b) this authority shall expire on 24 February 2023 or, if earlier, on the conclusion of the Company's next AGM;
  - (c) the Company may make any offer or agreement before such expiry which would or might require shares to be allotted or Allotment Rights to be granted after such expiry; and
  - (d) all authorities vested in the Directors on the date of the notice of this meeting to allot shares or to grant Allotment Rights that remain unexercised at the commencement of this meeting are revoked.

# NOTICE OF 2021 AGM

## CLINIGEN GROUP PLC

14. That, subject to the passing of resolution 13 in the notice of this meeting, the Directors are empowered pursuant to section 570 of the Companies Act 2006 to allot equity securities (as defined in section 560 of that Act) for cash, pursuant to the authority conferred on them by resolution 13 in the notice of this meeting or by way of sale of treasury shares, as if section 561 of that Act did not apply to any such allotment, provided that this power is limited to:

- (a) the allotment of equity securities in connection with any rights issue or open offer or any other pre-emptive offer that is open for acceptance for a period determined by the Directors to the holders of ordinary shares on the register on any fixed record date in proportion to their holdings of ordinary shares (and, if applicable, to the holders of any other class of equity security in accordance with the rights attached to such class), subject in each case to such exclusions or other arrangements as the Directors may deem necessary or appropriate in relation to fractions of such securities, the use of more than one currency for making payments in respect of such offer, any such shares or other securities being represented by depositary receipts, treasury shares, any legal or practical problems in relation to any territory or the requirements of any regulatory body or any stock exchange; and
- (b) the allotment of equity securities or sale of treasury shares (other than pursuant to sub-paragraph (a) above) to any person with an aggregate nominal value of £6,651.43,

and shall expire when the authority conferred on the Directors by resolution 13 in the notice of this meeting expires or is revoked, save that, before the expiry of this power, the Company may make any offer or agreement which would or might require equity securities to be allotted after such expiry.

15. That, subject to the passing of resolution 13 in the notice of this meeting and in addition to the power contained in resolution 14 set out in the notice of this meeting, the Directors are empowered pursuant to section 570 of the Companies Act 2006 to allot equity securities (as defined in section 560 of that Act) to any person for cash, pursuant to the authority conferred on them by resolution 13 in the notice of this meeting or by way of sale of treasury shares, as if section 561 of that Act did not apply to any such allotment, provided that this power is:

- (a) limited to the allotment of equity securities up to an aggregate nominal value of £6,651.43; and
- (b) used only for the purposes of financing (or refinancing, if the power is to be exercised within six months after the date of the original transaction) a transaction which the Directors determine to be an acquisition or other capital investment of a kind contemplated by the Statement of Principles on Disapplying Pre-Emption Rights most recently published by the Pre-Emption Group prior to the date of the notice of this meeting,

and shall expire when the authority conferred on the Directors by resolution 13 in the notice of this meeting expires or is revoked, save that, before the expiry of this power, the Company may make any offer or agreement which would or might require equity securities to be allotted after such expiry.

### Registered office:

Pitcairn House  
Crown Square  
Centrum 100  
Burton-on-Trent  
Staffordshire DE14 2WW

### By order of the Board

**Amanda Miller**  
Company Secretary  
30 September 2021

# NOTES

1. A member who is entitled to attend and vote at the AGM is entitled to appoint another person, or two or more persons in respect of different shares held by him, as his proxy to exercise all or any of his rights to attend, speak and vote at the AGM. A proxy need not also be a member.
2. A member must be registered as the holder of ordinary shares by 6:30pm on 22 November 2021 in order to be entitled to attend and vote at the AGM as a member in respect of those shares.
3. A form for the appointment of a proxy in respect of the AGM has been provided to members with this Notice of AGM. To be valid, a proxy appointment form must be completed in accordance with the instructions that accompany it and then delivered (together with any power of attorney or other authority under which it is signed, or a certified copy of such item) to Equiniti, Aspect House, Spencer Road, Lancing BN99 6DA so as to be received by 10:00am on 22 November 2021. Members who hold their shares in uncertificated form may also use 'the CREST voting service' to appoint a proxy electronically as explained in note 4 below.
4. CREST members who wish to appoint one or more proxies through the CREST system may do so by using the procedures described in 'the CREST voting service' section of the CREST Manual. CREST personal members or other CREST sponsored members, and those CREST members who have appointed one or more voting service providers, should refer to their CREST sponsor or voting service provider(s), who will be able to take the appropriate action on their behalf. In order for a proxy appointment or a proxy instruction made using the CREST voting service to be valid, the appropriate CREST message ('CREST proxy appointment instruction') must be properly authenticated in accordance with the specifications of CREST's operator, Euroclear UK & Ireland Limited ('Euroclear'), and must contain all the relevant information required by the CREST Manual. To be valid, the message (regardless of whether it constitutes the appointment of a proxy or is an amendment to the instruction given to a previously appointed proxy) must be transmitted so as to be received by Equiniti (ID RA19), as the Company's 'issuer's agent', by 10:00am on 22 November 2021. After this time any change of instruction to a proxy appointed through the CREST system should be communicated to the appointee through other means. The time of the message's receipt will be taken to be when (as determined by the timestamp applied by the CREST Applications Host) the issuer's agent is first able to retrieve it by enquiry through the CREST system in the prescribed manner. Euroclear does not make special procedures available in the CREST system for transmitting any particular message. Normal system timings and limitations apply in relation to the input of CREST proxy appointment instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member or a CREST sponsored member or has appointed any voting service provider(s), to procure that his CREST sponsor or voting service provider(s) take(s)) such action as is necessary to ensure that a message is transmitted by means of the CREST system by any particular time. CREST members and, where applicable, their CREST sponsors or voting service providers should take into account the provisions of the CREST Manual concerning timings as well as its section on 'Practical limitations of the system'. In certain circumstances the Company may, in accordance with the Uncertificated Securities Regulations 2001 or the CREST Manual, treat a CREST proxy appointment instruction as invalid.
5. You may not use any electronic address provided either in this document or any related documents (including the form of proxy) to communicate with the Company for any purpose other than those expressly stated.